Acute Exercise and Pancreatic Endocrine Function
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Behavioral: Exercise
- Registration Number
- NCT01812590
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
Subjects with type 2 diabetes will be stratified into two-quantiles based on ambient hyperglycemia (fasting glucose and HbA1c) and then the effects of a single aerobic exercise bout (1-hour at 50%VO2max) on pancreatic endocrine function will be determined.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Previous diagnosis with type 2 diabetes, or newly detected in our screening procedures
- Age 30-70 years
- BMI 20-40 kg/m2
Exclusion Criteria
- Treatment with insulin
- Contraindication to exercise as determined by ECG
- Pregnancy
- Active weight loss in the previous 6 months
- Actively engaged in exercise training programs
- Evidence of chronic pulmonary, cardiovascular, hepatic, renal, or hematological disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Exercise Trial Exercise Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
- Primary Outcome Measures
Name Time Method Pancreatic endocrine function 24-hours following a period of rest/exercise Insulin and glucagon secretory responses to intravenous glucose (hyperglycemic clamp 5.4 mmol/l above basal), glucagon-like peptide-1 (0.5 pmol/kg/min), and arginine (5 g injection) will be determined.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rigshospitalet
🇩🇰Copenhagen, Denmark